---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036563"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:28:57.577827+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest

## Summary
- Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.
- Cash and equivalents $87.1M as of Sep 30, 2023, excluding the $30M received in Oct.
- Net loss $11.3M ($0.16 per share) vs $12.0M ($0.17) in Q3 2022.
- Takeda anticipates regulatory filings for soticlestat in fiscal year 2024; two Phase 3 trials on track.
- OV329 expanding to IV formulation; IND expected H2 2024. OV350 (KCC2) IND also expected H2 2024.

## SEC filing metadata
- accession: 0001628280-23-036563
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/0001628280-23-036563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/ovid-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036563
- JSON: https://secwatch.observer/filing/0001628280-23-036563.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036563.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 3, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2023 Financial Results and Corporate Updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/0001628280-23-036563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.